Systemic Sclerosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Systemic Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Systemic Sclerosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Sclerosis Pipeline Outlook
Key Takeaways from the Systemic Sclerosis Pipeline Report
In June 2025, Novartis Pharmaceuticals announced a study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
In June 2025, GlaxoSmithKline conducted a study of an ongoing randomized controlled clinical study 218224 (Parent Study). The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.
DelveInsight's Systemic Sclerosis Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Systemic Sclerosis treatment.
The leading Systemic Sclerosis Companies such as Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others.
Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, Riociguat (Adempas, BAY63-2521), Bosentan, Imatinib mesylate, Belimumab, Rituximab, and others.
Stay ahead with the most recent pipeline outlook for Systemic Sclerosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Systemic Sclerosis Treatment Drugs
Systemic Sclerosis Emerging Drugs Profile
Iloprost: Eicos Sciences
Iloprost is a stable analogue of PGI2 and a potent prostacyclin (IP) receptor agonist. By mimicking PGI2, it is a vasodilator and inhibitor of platelet activation and fibrosis. Iloprost stimulates generation of cAMP by binding to the IP receptor, thereby affecting phospholipase activity and cytosolic calcium levels in platelets, fibroblasts, and endothelial cells. It is a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed and investigated in Phase III stage of development for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc).
ECCS 50: Cytori therapeutics
ECCS-50 (Cytori stem cell therapy) is a new treatment intended for the treatment of moderate to severe hand problems in people with scleroderma. It involves taking stem cells (a cell with the potential to become any cell type) from patient's fat tissue and reinjecting these cells into the hands. ECCS 50 are adipose derived stem and regenerative cells (ADRCs) taken from the patient's own tissue and prepared using Cytori's cellulation system before administration. ADRCs can be used to repair and regenerate a range of damaged or diseased tissue types by differentiation of the ASRCs along the specific cell lineage, thereby replacing the damaged or missing tissue.
Lenabasum (JBT-101): Corbus Pharmaceuticals
Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has acceptable safety and tolerability profiles without evidence of immunosuppression.
EHP-101: Emerald Health Pharmaceuticals
EHP-101 is an oral formulation of VCE-004.8, a synthetic aminoquinone derivative of CBD with dual peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid receptor type 2 (CB2) agonist activity. Both receptors are therapeutic targets for SSc. EHP-101 also modulates the hypoxia inducible factor (HIF) pathway, expanding the rationale for its development as a novel SSc drug. It is currently in phase II stage of development and is being developed by Emerald Health Pharmaceuticals.
The Systemic Sclerosis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Sclerosis Treatment.
Systemic Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Systemic Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Sclerosis market
Explore groundbreaking therapies and clinical trials in the Systemic Sclerosis Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Systemic Sclerosis Drugs
Systemic Sclerosis Companies
Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others.
Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type
Systemic Sclerosis Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Unveil the future of Systemic Sclerosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Sclerosis Market Drivers and Barriers
Scope of the Systemic Sclerosis Pipeline Report
Coverage- Global
Systemic Sclerosis Companies- Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others.
Systemic Sclerosis Pipeline Therapies- Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, Riociguat (Adempas, BAY63-2521), Bosentan, Imatinib mesylate, Belimumab, Rituximab, and others.
Systemic Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Systemic Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Systemic Sclerosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Sclerosis Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Systemic Sclerosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Iloprost: Eicos Sciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
EHP-101: Emerald Health Pharmaceuticals
Drug profiles in the detailed report…..
Early stage products (Phase I)
VIB7734: Viela Bio
Drug profiles in the detailed report…..
Inactive Products
Systemic Sclerosis Key Companies
Systemic Sclerosis Key Products
Systemic Sclerosis- Unmet Needs
Systemic Sclerosis- Market Drivers and Barriers
Systemic Sclerosis- Future Perspectives and Conclusion
Systemic Sclerosis Analyst Views
Systemic Sclerosis Key Companies
23. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/systemic-sclerosis-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
18 minutes ago
- Globe and Mail
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
Dividend income offers a great way to strengthen your overall financial position. It can potentially make you less dependent on the income you earn from a job, maybe even allowing you to work less or retire earlier than planned. Money doesn't buy happiness, but being less dependent on work to fund your lifestyle could be a contributor to a happier, less stressful life. A great way to build up dividend income is to invest in high-yielding dividend stocks that also happen to be lower-risk investments. Pfizer (NYSE: PFE), Realty Income (NYSE: O), and Bank of Nova Scotia (NYSE: BNS) are three attractive investments that you'll want to consider if you want to create a strong portfolio of income-generating stocks. Pfizer If you're looking for a high-yielding stock to hold for the long term, Pfizer is one you'll want to strongly consider. At 7.4%, its yield right now is more than five times what you'd get with the average stock on the S&P 500, which pays about 1.3%. Pfizer's stock is trading down more than 10% this year (as of the end of last week), as it can't seem to catch a break. While its valuation is modest -- it trades at 17 times its trailing earnings -- concerns about healthcare reform and the company's future growth prospects have made investors uneasy about the business and investing in it. But the healthcare company is still doing well and is on track to hit its guidance, which calls for revenue between $61 billion and $64 billion this year (comparable to how it did last year). It is also slashing costs to improve its bottom line. And it has been less than two years since it acquired oncology company Seagen, which may unlock more long-term growth for Pfizer in the future. Last year, the company also obtained approval from regulators for its first gene therapy in the U.S. -- Beqvez, a treatment for a genetic bleeding disorder. There's some uncertainty and risk with Pfizer, but there are opportunities as well. And at such a modest valuation, now can be an excellent time to add it to your portfolio. Pfizer has been a big name in healthcare for decades, and I don't think that's likely to change anytime soon. Realty Income One dividend stock I think all income investors should consider owning is Realty Income. This is a real estate investment trust (REIT) that not only offers a high yield of 5.8%, but it also pays a dividend every month. There's no need to wait around for multiple months, as is the case with other dividend stocks; with Realty Income, you're getting a much more regular stream of cash flow. The REIT has a diverse mix of tenants, which makes it an ideal option for long-term investors. It's diversified across industries and geographies, with more than 1,500 clients across 91 industries. The dividend remains well supported -- the REIT reported funds from operations (FFO) per share of $1.05 during the first three months of the year (versus $0.94 a year ago). That averages out to $0.35 per share per month, which is higher than the rate of its monthly dividend of $0.2685. REITs use FFO to assess how much they can afford to pay in dividends, and with Realty Income's financials looking solid, there aren't any significant risks with its payout. Share prices of Realty Income are up 5% this year, and this can be a great income-generating investment to add to your portfolio for the long haul. Bank of Nova Scotia Rounding out this list of high-yielding dividend stocks is Canada-based Bank of Nova Scotia, also known as Scotiabank. At around 6%, that's a high payout for a top bank stock that is known for long-term stability. It declared its first dividend back in 1833 and has continued making regular payments since then. The bank increased its provision for credit losses in its most recent quarter, in a sign of growing concern about macroeconomic conditions. Scotiabank's net income totaled over $2 billion Canadian dollars for the period ending April 30, which was nearly identical to its bottom line in the prior-year period. There are concerns about how the Canadian economy may perform in the near future due to tariffs, but in the grand scheme of things, that may prove to be a short-term concern for investors who are willing to hang on for years. Scotiabank's impressive track record and resilience over the years should inspire some confidence in the business. The bank stock has increased its dividend by more than 22% in four years and can be an excellent option to hang on to for the long term. Not only can you collect a high yield today, but the dividend income you get from this investment can rise over the years. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
33 minutes ago
- Globe and Mail
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. 1. Most of the company's problems should be temporary I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. 2. The two biggest threats to UnitedHealth Group are iffy I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. 3. The price is right Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
CBC
an hour ago
- CBC
'Enough is enough:' Local politicians decry Niagara Health's decision to reduce urgent care hours
Niagara Health's decision to reduce summer hours at its only two urgent care centres in Fort Erie and Port Colborne, Ont., has sparked outrage. Some local elected officials in Fort Erie are calling on the CEO to resign, the provincial government to intervene and an immediate reversal of the decision. Mayor Wayne Redekop told his council Monday evening that the people running the local hospital system "don't give a rats ass about Fort Erie." His perspective was echoed by other councillors, including Nick Dubanow. "I think we need to kick Niagara Health to the curb," he said. "I'm very angry. Enough is enough." Earlier that day, Niagara Health had announced that throughout July, August and early September, it will close the Fort Erie Urgent Care Centre on Fridays and the Port Colborne Urgent Care Centre on Saturdays. Both centres will be closed on Canada Day, July 1, and the Labour Day long weekend, Aug. 30 to Sept. 1. Fort Erie's will also be closed on the Civic Holiday long weekend, Aug. 1 to 4. Normally they operate seven days a week. Fort Erie Coun. Tom Lewis advised council on Monday he will be putting forward two motions later this month. The first will call for the town to "immediately withhold" committed funding to Niagara Health's new hospital, although it's unclear the dollar amount. The second will call for the Niagara Health CEO Lynn Guerriero and members of the board to resign, and for the province to appoint a supervisor to oversee operations, Lewis said. "Niagara Health has broken our trust," he said. "We owe it to the people of Fort Erie to take a firm stance. And I believe this council will." Niagara Health said in a statement to CBC Hamilton local officials are oversimplifying the complexity of running a regional hospital system. "We are disappointed when misinformation is shared by elected local officials in their zeal to build support for their campaigns," said spokesperson Erica Bajer. Doctor shortage prompts closures The closures are because the region faces a shortage of physicians qualified to work in emergency departments, Niagara Health said in a news release. The doctors who'd normally work in urgent care need to be deployed to hospitals and even still many shifts there remain unfilled. "We know these closures are frustrating and concerning for the communities affected, said Dr. Kevin Chan, chief of staff, in the release. "They are not decisions we made lightly. This is the minimum level of closure required to maintain emergency care across the region." There are no hospitals or emergency rooms in Fort Erie or Port Colborne and thousands of people are without a family doctor. The closest hospital is in Welland — about a 12-kilometre drive from Port Colborne and 32-kilometre drive from Fort Erie. Niagara Health also runs a hospital in St. Catharines and another in Niagara Falls. Urgent care centres are supposed to be for people with health conditions who can't wait for a scheduled medical appointment but don't necessarily need emergency care, says Niagara Health's website. Those health conditions include nausea, vomiting, fevers, flu, minor cuts that may need stitches, sports injuries, ear, throat and eye problems and minor asthma flare-ups or allergic reactions. Niagara Health said the urgent care closures are despite "exhaustive efforts" to recruit physicians including financial incentives, direct outreach, targeted recruitment campaigns and flexible scheduling. "Further, Niagara Health is working tirelessly to recruit more physicians to the region and it's disingenuous to minimize the incredible challenge of physician recruitment in the face of a province-wide doctor shortage," said Bajer. In 2009, Niagara Health converted Fort Erie's Douglas Memorial Hospital's emergency department to an urgent care centre. In 2023, it reduced hours at both centres from operating overnight to closing in the evening. It's also planning to close them permanently in 2028 when a new hospital in Niagara Falls is supposed to open. 'Treated as afterthoughts," mayor says At a news conference Wednesday, Redekop and Port Colborne Mayor Bill Steele said they don't believe Niagara Health had a plan to keep the urgent care centres running seven days a week despite thousands of tourists visiting throughout the summer. "I'm concerned we're being treated as afterthoughts and it's becoming normalized," Steele said. They mayors were also joined by local NDP MPP Wayne Gates. Steele and Redekop said they spoke with the Niagara Health CEO in May, where she gave them a heads up of staffing shortages that could impact urgent care. The mayors said they could help to recruit physicians and in a follow-up email requested to see the Niagara Health recruitment program, and the number of doctors needed, but never heard back. Then on Monday, they had a call with Chan, the chief of staff. He advised them of the reduced hours, which Niagara Health made public during their meeting, Redekop said. No heads up was given to the mayors or councillors. Redekop said at the meeting they also learned Niagara Health doesn't have a formal physician recruitment program or plan to develop a training program so family doctors can more easily become qualified to work in urgent care and emergency departments. Niagara Health said it does "aggressive and ongoing recruitment efforts" that aren't limited to "a single campaign" and provided this "clarification" to the mayors on Monday. Bajer said Niagara Health sent information about its training process to them on Wednesday. But Niagara Health also didn't post its physician schedules for the urgent care centres two months in advance as it normally does to give doctors who want more hours the opportunity to take them, Redekop said. The hospital system said its process was delayed "as we worked to stabilize physician coverage across the entire hospital system, particularly in emergency departments, which are provincially mandated to remain operational." Ministry says up to Niagara Health to decide Several Fort Erie councillors said they didn't believe Niagara Health tried to keep the urgent care centres open, even as it will force more people to go to already busy hospitals for health care. "The hospital system is effectively condemning its own emergency room," said Coun. Joan Christensen at Monday's council meeting, after having also joined the phone call with Niagara Health earlier in the day. "In my opinion, our battle should now be with the Government of Ontario. We can't negotiate with people who are consistently misrepresenting the truth." The Ministry of Health said in a statement it is up to Niagara Health's to decide how to deliver services. "While the Ministry of Health was not directly involved in this decision, we will continue to work closely with Niagara Health and other hospital partners ... to ensure they have the tools they need to deliver high-quality care close to home," said press secretary Ema Popovic.
